Trial Profile
Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Diacerein (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DGCLFT2DM
- 02 May 2018 Status changed from active, no longer recruiting to completed.
- 15 Sep 2017 Primary endpoint has been met. (mean changes in HbA 1c compared to placebo) as per results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes